Expert Highlights CAR T-Cell Breakthroughs – OncLive
OncLive |
Expert Highlights CAR T-Cell Breakthroughs
OncLive The oncology community saw the first FDA approval of a chimeric antigen receptor (CAR) T-cell therapy in August 2017, when tisagenlecleucel (Kymriah) was approved for the treatment of patients up to 25 years of age with B-cell precursor acute … CAR T-Cell Therapy Is Making Untreatable Cancer Treatable Mayo Clinic to Offer CAR T-Cell Therapy for Relapsed Non-Hodgkin Lymphoma |
